journal
MENU ▼
Read by QxMD icon Read
search

Journal of Dermatological Treatment

journal
https://www.readbyqxmd.com/read/30554541/the-journey-for-us-psoriasis-patients-prescribed-a-topical-a-retrospective-database-evaluation-of-patient-progression-to-oral-and-or-biologic-treatment
#1
Jashin J Wu, Minyi Lu, Karen A Veverka, Maartje Smulders, Eros Papademetriou, Junhua Yu, Steven R Feldman
BACKGROUND: A specific sequence for psoriasis (PsO) therapy has not been defined. OBJECTIVES: This retrospective, observational cohort study characterized pathways of PsO treatment over 3 years for newly diagnosed patients initially treated with a topical medication. METHODS: Adult PsO patients from the Explorys database (March 1 2011 to June 30 2015) were grouped according to medication-use patterns: 1) discontinued therapy; 2) topical therapy only; 3) switched/added an oral agent; and 4) switched/added a biologic agent...
December 17, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/30526155/secukinumab-in-the-therapy-of-psoriasis-and-psoriatic-arthritis-a-safe-choice-in-clinical-practice
#2
Andrea Chiricozzi
No abstract text is available yet for this article.
December 8, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/30526156/omalizumab-treatment-in-patients-with-severe-chronic-spontaneous-urticaria-consideration-from-real-life-experience-in-italy
#3
Riccardo Asero
No abstract text is available yet for this article.
December 7, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/30513061/recurrent-oedema-of-the-uvula-in-a-patient-with-chronic-spontaneous-urticaria-successfully-treated-with-omalizumab
#4
A Pannofino
Uvula oedema is a condition characterized by a sensation of a foreign body in the oropharynx and difficulty to speak; sometimes, if associated to glottis oedema, difficulty to breathe and dysphonia are also present. Urticaria is a disease characterized by itching wheals on the skin, and sometimes angioedema. Chronic urticaria is spontaneous when the aetiology is unknown. Chronic urticaria may be disabling and difficult to treat, with a negative impact on the patient's quality of life. Omalizumab administration is suggested for refractory patients as add-on therapy to the antihistamines, in a third line...
December 4, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/30513060/rapid-persistent-and-simultaneous-remission-of-urticaria-and-severe-atopic-dermatitis-after-treatment-with-omalizumab
#5
E Del Duca, M Esposito, S Lechiancole, A Giunta, L Bianchi
This article reports the rapid and complete remission of concomitant chronic spontaneous urticaria and atopic dermatitis, obtained in a woman of 32 years, after treatment with omalizumab, without adverse events.
December 4, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/30513014/randomized-controlled-trial-on-a-prp-like-cosmetic-biomimetic-peptides-based-for-the-treatment-of-alopecia-areata
#6
Rinaldi Fabio, Marzani Barbara, Pinto Daniela, Sorbellini Elisabetta
Background Alopecia areata (AA) is a non-scarring auto-immune hair disorder. Recent researches explained the role of growth factors (GFs) in hair follicle cycling. The main reservoir of GFs are alpha-granules of platelets and novel procedures have been implemented aimed at collecting platelet-rich plasma (PRP). PRP has been safely implemented in many medical application and has also been successfully used as alternative cell-based therapies for the treatment of hair growth disorder, among which also AA. Objectives By mean of a randomized double-blinded, placebo and active-controlled, parallel group study we have studied the efficacy of a cosmetic product (named TR-M-PRP plus) comprising biomimetic peptides specific for hair growth mimicking PRP composition for the treatment of AA...
December 4, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/30501539/oral-small-molecules-for-the-treatment-of-atopic-dermatitis-a-systematic-review
#7
Pezhman Mobasher, Mehran Heydari Seradj, Jodie Raffi, Margit Juhasz, Natasha Atanaskova Mesinkovska
INTRODUCTION: Atopic dermatitis (AD) is a chronic, inflammatory skin disease. Conventional treatments include topical emollients, corticosteroids, calcineurin inhibitors, phototherapy, and systemic immunomodulatory agents, however, these medications have limitations in the treatment of moderate to severe AD. Current literature demonstrates that oral small molecules may be an effective modality to treat AD. METHOD: Using PubMed/MEDLINE, Embase, Cochrane Skin databases and clinicaltrials...
December 2, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/30497304/patient-reported-outcomes-for-intensified-versus-conventional-nb-uvb-treatment-in-non-segmental-vitiligo
#8
Sanne E Uitentuis, Vidhya S Narayan, Bas S Wind, Marcel W Bekkenk, Menno A de Rie, Albert Wolkerstorfer
INTRODUCTION: Treatment of non-segmental vitiligo (NSV) remains a challenge. Efficacy of NB-UVB treatment may increase with more frequent use or in combination with topical agents. Currently, data on the most effective treatment regimen lacking. Our objective is to retrospectively compare NB-UVB treatment regimens for non-segmental vitiligo. METHODS: Patients with NSV treated with NB-UVB therapy were included in two time periods. Group I received NB-UVB therapy twice a week (conventional treatment) and group II received NB-UVB thrice a week, combined with topical agents (intensified treatment)...
November 29, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/30222012/rebound-of-atopic-dermatitis-as-a-complication-of-using-systemic-glucocorticoids-a-myth-or-a-fact
#9
Amanda D Mansouri, Arash Taheri, Parisa Mansoori
No abstract text is available yet for this article.
November 29, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/30220226/platelet-rich-plasma-is-a-useful-therapeutic-option-in-melasma
#10
Eman R M Hofny, Amira A Abdel-Motaleb, Alaa Ghazally, Asmaa Mahmoud Ahmed, Mahmoud Rezk Abdelwahed Hussein
BACKGROUND: Melasma is a cosmetically disfiguring disorder of facial pigmentation. OBJECTIVES: We evaluated the value of platelet-rich plasma (PRP) in the treatment of melasma using two different delivery techniques: microneedling using dermapen versus microinjections using mesoneedles. PATIENTS AND METHODS: Twenty-three adult Egyptian melasma patients were enrolled. Wood's light was used to determine the histological type of melasma. Autologous PRP was delivered into the lesional melasma skins through microneedling with dermapen on the right side of the face and intradermal microinjections using mesoneedles on the left side of the face (for each patient)...
November 29, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/30482111/serum-ykl-40-in-patients-with-psoriasis-vulgaris-treated-by-narrow-band-uvb-phototherapy
#11
Mohammed Abu El-Hamd, Moustafa Adam El Taieb, Abdallah Abdallah Mahmoud, Ola Mahmoud Samy
BACKGROUND: Psoriasis is a common chronic and immune-mediated inflammatory skin disease. OBJECTIVES: This study aimed to investigate the serum levels of Chitinase-3-like protein 1 (YKL-40) in patients with psoriasis vulgaris before and after narrow-band ultraviolet B (NB-UVB) phototherapy. METHODS: This study was designed as a cross-sectional case-control. This study included 30 patients with psoriasis vulgaris and 20 healthy individuals. Psoriasis Area and Severity Index (PASI) score were used to evaluate the patients with psoriasis vulgaris before and after treatment...
November 28, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/30321080/adverse-cutaneous-effects-of-neratinib
#12
Ramiz N Hamid, Christine S Ahn, William W Huang
Neratinib is a tyrosine kinase inhibitor that was FDA-approved for extended adjuvant treatment in adults with human epidermal growth factor receptors-2 (HER-2) positive breast cancer in 2017. Due to the novelty of the drug, there are no current reports in the literature of adverse cutaneous effects associated with neratinib therapy. We present a case of a woman on neratinib for HER-2 positive infiltrating ductal carcinoma of the right breast who presented to the dermatology clinic with changes to the fingernails, acne, and a rash on the face...
November 28, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/30482070/treatment-goals-in-psoriasis-from-a-patient-perspective-a-qualitative-study
#13
Tessa A Kouwenhoven, Jeroen A M van der Ploeg, Peter C M van de Kerkhof
BACKGROUND: Psoriasis is a chronic inflammatory skin disorder with marked impact on quality of life. In view of the well-recognized need to integrate the patient perspective in psoriasis care, treatment goals which originate entirely from the experiences of the patients are of utmost importance. OBJECTIVE: To explore treatment goals in patients with psoriasis that originate entirely from the patient perspective. METHODS: Data was generated using face-to-face in-depth interviews with 15 Dutch psoriasis patients, which were analysed using template analysis resulting in 2 first-level, 10 second-level and 14 third-level themes...
November 27, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/30474443/treatment-outcome-and-persistence-of-repigmentation-from-narrow-band-ultraviolet-b-phototherapy-in-vitiligo
#14
Narumol Silpa-Archa, Puncharas Weerasubpong, Natchaya Junsuwan, Punyanut Yothachai, Orawan Supapueng, Chanisada Wongpraparut
BACKGROUND: Narrow-band ultraviolet B (NB-UVB) phototherapy is a mainstay treatment in vitiligo. However, data relative to repigmentation outcome, prognostic factors, and duration of repigmentation are limited. OBJECTIVES: To investigate the quantitative repigmentation outcome of NB-UVB phototherapy in vitiligo, the factors associated with favorable prognosis after NB-UVB, and the duration of repigmentation after NB-UVB discontinuation. MATERIALS AND METHODS: Medical records of vitiligo patients who underwent NB-UVB phototherapy at Department of Dermatology, Siriraj Hospital during 2012 to 2016 were retrospectively reviewed...
November 25, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/30470146/patient-preferences-for-attributes-of-topical-anti-psoriatic-medicines
#15
V Vasconcelos, A Teixeira, V Almeida, M Teixeira, S Ramos, T Torres, J M Sousa Lobo, I F Almeida
Background Patient preferences should be considered when prescribing topical treatments to drive up adherence and improve clinical outcomes. Objetive The aim of this work was to identify the most important attributes of topical medicines for psoriasis treatment in the patients' view, and explore the sociodemographic and clinical determinants of these preferences. Methods A questionnaire for the evaluation of the relevancy given to specific attributes of topical medicines used for psoriasis treatment was developed (PSO-TOPAP) and was applied to a total of seventy-nine patients, members of the Portuguese Association of Psoriasis (PSOPortugal) or outpatients of a dermatology unit of a central hospital...
November 23, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/30462560/chronic-spontaneous-urticaria-treated-with-omalizumab-report-of-two-cases
#16
Giovanna Malara, Claudio Sciarrone
Chronic spontaneous urticaria (CSU) is a relatively common skin disease whose etiopathogenesis, as well as other factors influencing disease manifestations, are not fully understood. Mast cell function is recognised as having a central role in CSU signs and symptoms. Therapeutic options are limited; a number of drugs, recommended by international guidelines for the management of urticaria, lack regulatory approval for CSU and are prescribed off label. Omalizumab, a recombinant humanized anti IgE antibody, has recently received the approval for CSU treatment in Europe after an appropriate clinical development...
November 21, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/30462557/omalizumab-treatment-in-a-12-year-old-girl-with-chronic-spontaneous-urticaria
#17
Giuseppe Fabio Parisi, Maria Papale, Lucia Giovanna Tardino, Sara Manti, Caterina Cuppari, Carmelo Salpietro, Salvatore Leonardi
Omalizumab is a recombinant humanized IgG monoclonal antibody, which binds the Fc region of free IgE prevent its binding to its high-affinity receptor (FcεR1) on mast cells and basophils. Omalizumab was approved as add-on therapy for moderate-to-severe persistent allergic asthma and for patients with chronic spontaneous urticaria resistant to antihistamine treatment. This article reports effective and safe treatment of a 12 years old girl with add-on omalizumab.
November 21, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/30457412/youtube-videos-on-oral-systemic-therapies-for-psoriasis-a-cross-sectional-analysis
#18
Kelly A Reynolds, Deeti J Pithadia, Erica B Lee, Jashin J Wu
No abstract text is available yet for this article.
November 20, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/30256686/dose-increase-beyond-labelled-dose-of-biologics-is-associated-with-incremental-pharmacy-costs-results-from-a-real-world-study-in-the-uk
#19
Anthony Bewley, Cristiana Miglio, Haijun Tian, Isabelle Gilloteau, Joannah Whitehead, Ruben Hermans
BACKGROUND: There is limited evidence regarding biologics dosing patterns and its costs among psoriasis patients in the United Kingdom (UK). OBJECTIVE: This retrospective study assessed biologics dose increase beyond labelled dose and associated UK pharmacy costs in moderate to severe psoriasis patients. METHODS: Adult psoriasis patients on biologic prescription for ≥12 continuous months between January 2010 and March 2015 with their diagnosis recorded in the UK Hospital Treatment Insights Database within one month of such prescription were included...
November 19, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/30244619/treatment-of-rosai-dorfman-disease-with-oral-bexarotene-a-case-series
#20
Shamir Geller, Klaus Busam, Paul A Hamlin, Alison J Moskowitz, Steven M Horwitz, Patricia L Myskowski
BACKGROUND: Rosai-Dorfman disease (RDD) is a rare histiocytic proliferative disorder of unknown etiology. The skin is the most frequent extranodal site of RDD involvement and may be the only organ involved. While RDD is an indolent self-limited disease, treatment is needed in patients with extensive, persistent or progressive disease, or if cosmetic disfigurement or physical impairment significantly affects the patient. There is no specific treatment for RDD, and multiple therapeutic approaches have been described with variable success rates...
November 19, 2018: Journal of Dermatological Treatment
journal
journal
30315
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"